Third Wave to Launch Warfarin, HPV Dxs In 06, 07 as Part of Long-Term Revamp | GenomeWeb

Third Wave hopes to revive its slumping revenues partly with new diagnostics, including a test to help guide warfarin treatment and another to detect human papilloma virus.

The company this week posted disappointing fourth-quarter earnings featuring a 28-percent drop in revenues and an increase in losses year over year. In a conference call with investors, Third Wave officers presented the quarter's results alongside a three-point plan to boost its prospects in the long term as it continues its fitful switch to molecular diagnostics from genomics tools.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.